Showing results (51-60 of 141) with videos related to

Sort By:
Pageof 15
Clinical and Experimental Immunology|January 24, 2009
Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferationS Thomas, I Przesdzing, D Metzke, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|March 30, 2013
Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cellsAndreas Fischer, Markus Gluth, Ulrich-Frank Pape, et al.
Advances in Clinical Chemistry|October 9, 2016
Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical PhenotypeD Roggenbuck, D Reinhold, D C Baumgart, et al.
Journal of Crohn'S & Colitis|April 3, 2012
What changes in inflammatory bowel disease management can be implemented today?Edouard Louis, Daniel C Baumgart, Subrata Ghosh, et al.
The Journal of Sports Medicine and Physical Fitness|July 30, 2014
Relationship between core strength and key variables of performance in elite rink hockey playersM W Hoppe, J Freiwald, C Baumgart, et al.
The American Journal of Gastroenterology|December 19, 2012
Risk factors in the development of esophageal adenocarcinomaHeiko Pohl, Katharina Wrobel, Christian Bojarski, et al.
The American Journal of Gastroenterology|February 26, 2009
Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's diseaseDaniel C Baumgart, James N Lowder, Stephan R Targan, et al.
International Journal of Colorectal Disease|November 9, 2011
The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of actionMatthias Prager, Janine Büttner, Verena Haas, et al.
Pageof 15